| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BIOPSYCH.2004.10.033 |
| P698 | PubMed publication ID | 15691522 |
| P50 | author | Terence A Ketter | Q75471107 |
| Robert M. Post | Q87613308 | ||
| P2093 | author name string | David A Luckenbaugh | |
| Robert T Dunn | |||
| Mark W Willis | |||
| Tim A Kimbrell | |||
| John T Little | |||
| Brenda E Benson | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 220-228 | |
| P577 | publication date | 2005-02-01 | |
| P1433 | published in | Biological Psychiatry | Q4914961 |
| P1476 | title | Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression | |
| P478 | volume | 57 |
| Q34465386 | Amplitude of low-frequency oscillations in first-episode, treatment-naive patients with major depressive disorder: a resting-state functional MRI study |
| Q48375825 | Anterior cingulate cortex and cerebellar hemisphere neurometabolite changes in depression treatment: A 1H magnetic resonance spectroscopy study |
| Q35592041 | Baseline brain metabolism in resistant depression and response to transcranial magnetic stimulation |
| Q24623453 | Brain SPECT Imaging in Complex Psychiatric Cases: An Evidence-Based, Underutilized Tool |
| Q26786239 | Brain Structural Effects of Antidepressant Treatment in Major Depression |
| Q51647299 | Cerebellar hyperactivity during smooth pursuit eye movements in bipolar disorder |
| Q30906677 | Chronic SSRI stimulation of astrocytic 5-HT2B receptors change multiple gene expressions/editings and metabolism of glutamate, glucose and glycogen: a potential paradigm shift |
| Q43296887 | Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation |
| Q37012874 | Chronic vagus nerve stimulation for treatment-resistant depression decreases resting ventromedial prefrontal glucose metabolism |
| Q30499591 | Determination of hemispheric emotional valence in individual subjects: a new approach with research and therapeutic implications |
| Q30369880 | Differential abnormalities of functional connectivity of the amygdala and hippocampus in unipolar and bipolar affective disorders. |
| Q33953490 | Differential effects of serotonergic and noradrenergic antidepressants on brain activity during a cognitive control task and neurofunctional prediction of treatment outcome in patients with depression |
| Q46936349 | Differential modulation of emotion processing brain regions by noradrenergic and serotonergic antidepressants |
| Q43235413 | Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. |
| Q34660500 | Effects of duloxetine treatment on brain response to painful stimulation in major depressive disorder |
| Q46477533 | Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. |
| Q37120158 | Electroencephalographic alpha measures predict therapeutic response to a selective serotonin reuptake inhibitor antidepressant: pre- and post-treatment findings. |
| Q34391633 | Fluoxetine and all other SSRIs are 5-HT2B Agonists - Importance for their Therapeutic Effects |
| Q34565649 | Frontocingulate dysfunction in depression: toward biomarkers of treatment response |
| Q33550538 | Functional neuroimaging studies of bipolar disorder: examining the wide clinical spectrum in the search for disease endophenotypes. |
| Q35731471 | Identifying predictors, moderators, and mediators of antidepressant response in major depressive disorder: neuroimaging approaches |
| Q33404025 | Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures. |
| Q30927398 | In pursuit of neuroimaging biomarkers to guide treatment selection in major depressive disorder: a review of the literature |
| Q33816541 | Medial prefrontal cortex activity during memory encoding of pictures and its relation to symptomatic improvement after citalopram treatment in patients with major depression |
| Q36401907 | Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets |
| Q30903129 | Neuroimaging-based biomarkers for treatment selection in major depressive disorder |
| Q36503244 | Predicting therapeutic response to secondary treatment with bupropion: dichotic listening tests of functional brain asymmetry |
| Q55002697 | Prediction of response to drug therapy in psychiatric disorders. |
| Q35237042 | Predictors, moderators, and mediators (correlates) of treatment outcome in major depressive disorder. |
| Q52594008 | Pretreatment Rostral Anterior Cingulate Cortex Theta Activity in Relation to Symptom Improvement in Depression: A Randomized Clinical Trial. |
| Q36687563 | Pretreatment cerebral metabolic activity correlates with antidepressant efficacy of vagus nerve stimulation in treatment-resistant major depression: a potential marker for response? |
| Q37246380 | Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment |
| Q47666907 | Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years |
| Q27006485 | Signal Transduction in Astrocytes during Chronic or Acute Treatment with Drugs (SSRIs, Antibipolar Drugs, GABA-ergic Drugs, and Benzodiazepines) Ameliorating Mood Disorders |
| Q48413926 | Specific ways brain SPECT imaging enhances clinical psychiatric practice |
| Q37911004 | Surrogate markers of treatment outcome in major depressive disorder |
| Q37811198 | The WAG/Rij strain: A genetic animal model of absence epilepsy with comorbidity of depressiony |
| Q39431425 | Tissue Type-Specific Bioenergetic Abnormalities in Adults with Major Depression |
| Q35549737 | Toward a neuroimaging treatment selection biomarker for major depressive disorder |
| Q38269358 | Toward the application of functional neuroimaging to individualized treatment for anxiety and depression |
Search more.